ReviewPediatric nephrology (Berlin, Germany)2012
Genetic testing in renal disease.
Review in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Noninvasive genetic testing for type IV collagen nephropathy using oral mucosa DNA sampling in children with haematuria.Renal failure · 2024Article
- Consanguineous Marriage and Its Association With Genetic Disorders in Saudi Arabia: A Review.Cureus · 2024Review
- Shockwaves and the Rolling Stones: An Overview of Pediatric Stone Disease.Kidney international reports · 2023Review
- Genetic Testing in the Pediatric Nephrology Clinic: Understanding Families' Experiences.Journal of pediatric genetics · 2022Article
- Is my PET in my genes?Pediatric nephrology (Berlin, Germany) · 2022Article
- A practical approach to the genomics of kidney disorders.Pediatric nephrology (Berlin, Germany) · 2022Review
- Screening for an Underlying Tubulopathy in Children With Growth Failure, Simply Maths?Frontiers in pediatrics · 2022Article
- Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome.Journal of the American Society of Nephrology : JASN · 2019Article
- OVAS: an open-source variant analysis suite with inheritance modelling.BMC bioinformatics · 2018Article
- Potential and pitfalls in the genetic diagnosis of kidney diseases.Clinical kidney journal · 2017Article
- Fainting Fanconi syndrome clarified by proxy: a case report.BMC nephrology · 2017Article
- The nephrologist of tomorrow: towards a kidney-omic future.Pediatric nephrology (Berlin, Germany) · 2017Review
- Outcome of Multi-Cystic Dysplastic Kidneys in Children.Iranian journal of pediatrics · 2015Article
- Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.Nature reviews. Nephrology · 2015Review
- Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.Molecular genetics & genomic medicine · 2015Article
- Pediatric Nephrology in Primary Care: The Forest for the Trees.Frontiers in public health · 2015Article
- Renal artery stenosis in association with congenital anomalies of the kidney and urinary tract.Saudi medical journal · 2014Article
- DNA variant databases improve test accuracy and phenotype prediction in Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2014Review
- The blind kidney: disorders affecting kidneys and eyes.Pediatric nephrology (Berlin, Germany) · 2013Review
- NPHS2 homozygous p.R229Q variant: potential modifier instead of causal effect in focal segmental glomerulosclerosis.Pediatric nephrology (Berlin, Germany) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
A revolution is happening in genetics! The decoding of the first genome in 2003 was a large international collaborative effort that took about 13 years at a cost of around $2.7 billion. Now, only a few years later, new technology allows the sequencing of an entire genome within a few weeks--and at a cost of less than $10,000. The vaunted $1000 genome is within reach. These extraordinary advances will undoubtedly transform the way we practice medicine. But, like any new technology, it carries risks, as well as benefits. As physicians, we need to understand the implications in order to best utilise these advances for our patients and to provide informed advice. In this review, our aim is to explain these new technologies, to separate the hype from the reality and to address some of the resulting questions and implications. The practical objective is to provide a simple overview of the available technologies and of purpose to which they are best suited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.